aminoglutethimide has been researched along with Lymph Node Metastasis in 16 studies
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.
aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 9.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 9.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 9.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "3 months, women who received anastrozole (n = 387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer, or distant metastasis) compared with women who received no further treatment (n = 469; hazard ratio = 0." | 5.12 | Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. ( Dadak, C; Gnant, M; Greil, R; Hofbauer, F; Jakesz, R; Kubista, E; Kwasny, W; Mlineritsch, B; Renner, K; Rücklinger, E; Samonigg, H; Schmid, M; Stierer, M; Tausch, C, 2007) |
| "In order to evaluate the effectiveness of second and third line hormone therapy for postmenopausal (spontaneous or surgical) women with metastatic tamoxifen-resistant breast cancer, 293 women aged 36 to 91 (mean 63." | 5.07 | [2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients]. ( Ayme, Y; Carton, M; Daban, A; Delozier, T; Fargeot, P; Ferri, L; Fumoleau, P; Garcia-Giralt, E; Gorins, A; Omodei Zorini, C, 1994) |
| "The study purpose was to evaluate aminoglutethimide (AG) as adjuvant therapy in patients with primary node-positive breast cancer in a randomized double-blind placebo-controlled trial." | 5.07 | Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. ( Coombes, RC; Easton, D; Ford, HT; Jones, AL; Law, M; McKinna, JA; Nash, A; Powles, TJ; Smith, IE; Tidy, A, 1992) |
| "Three hundred and twenty-two postmenopausal patients with primary breast cancer and ipsilateral axillary node involvement were randomized to receive aminoglutethimide and hydrocortisone or placebo for 2 years in a double blind randomized trial between April 1980 and March 1985." | 5.06 | Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. ( Bradbeer, J; Chilvers, C; Coombes, RC; Easton, D; Ford, HT; McKinna, A; Powles, TJ; Smith, IE; White, H; Yarnold, J, 1987) |
| "Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months)." | 1.28 | Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. ( Angus, B; Cairns, J; Farndon, J; Harris, AL; Horne, CH; Nicholson, S; Sainsbury, JR; Wright, C, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 8 (50.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hobdy, EM | 1 |
| Shafi, NQ | 1 |
| Kummar, S | 1 |
| Jakesz, R | 1 |
| Greil, R | 1 |
| Gnant, M | 1 |
| Schmid, M | 1 |
| Kwasny, W | 1 |
| Kubista, E | 1 |
| Mlineritsch, B | 1 |
| Tausch, C | 1 |
| Stierer, M | 1 |
| Hofbauer, F | 1 |
| Renner, K | 1 |
| Dadak, C | 1 |
| Rücklinger, E | 1 |
| Samonigg, H | 1 |
| Beccati, MD | 1 |
| Degli Azzi Vitelleschi, I | 1 |
| Marangolo, M | 1 |
| Semiglazov, VF | 1 |
| Ivanov, VG | 1 |
| Moiseenko, VM | 1 |
| Bershteĭn, LM | 1 |
| Ivanova, OA | 1 |
| Tsyrlina, EV | 1 |
| Barash, NIu | 1 |
| Bozhok, AA | 1 |
| Garcia-Giralt, E | 1 |
| Omodei Zorini, C | 1 |
| Ferri, L | 1 |
| Ayme, Y | 1 |
| Carton, M | 1 |
| Daban, A | 1 |
| Delozier, T | 1 |
| Fargeot, P | 1 |
| Fumoleau, P | 1 |
| Gorins, A | 1 |
| Bonneterre, J | 1 |
| Adenis, A | 1 |
| Pion, JM | 1 |
| Cambier, L | 1 |
| Kamus, E | 1 |
| Hecquet, B | 1 |
| Cameron, DA | 1 |
| Anderson, ED | 2 |
| Levack, P | 1 |
| Hawkins, RA | 2 |
| Anderson, TJ | 2 |
| Leonard, RC | 2 |
| Forrest, AP | 2 |
| Chetty, U | 2 |
| Scott, RD | 1 |
| Wright, C | 1 |
| Nicholson, S | 2 |
| Angus, B | 1 |
| Sainsbury, JR | 1 |
| Farndon, J | 1 |
| Cairns, J | 1 |
| Harris, AL | 1 |
| Horne, CH | 1 |
| Jones, AL | 1 |
| Powles, TJ | 3 |
| Law, M | 1 |
| Tidy, A | 1 |
| Easton, D | 3 |
| Coombes, RC | 3 |
| Smith, IE | 3 |
| McKinna, JA | 1 |
| Nash, A | 1 |
| Ford, HT | 2 |
| Henry, JA | 1 |
| Piggott, NH | 1 |
| Mallick, UK | 1 |
| Farndon, JR | 1 |
| Westley, BR | 1 |
| May, FE | 1 |
| Jonat, W | 1 |
| Maass, H | 1 |
| Lönning, PE | 1 |
| Wiedemann, G | 1 |
| Kvinnsland, S | 1 |
| Lundgren, S | 1 |
| Chilvers, C | 2 |
| Thomas, L | 1 |
| Adcock, H | 1 |
| Gazet, JC | 1 |
| Nash, AG | 1 |
| Bradbeer, J | 2 |
| McKinna, A | 1 |
| White, H | 1 |
| Yarnold, J | 1 |
7 trials available for aminoglutethimide and Lymph Node Metastasis
| Article | Year |
|---|---|
Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.
Topics: Aged; Aged, 80 and over; Aminoglutethimide; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase | 2007 |
[2d and 3d line hormonal therapy in postmenopausal metastatic breast tumor. Comparison of medroxyprogesterone acetate and aminoglutethimide in tamoxifen-resistant patients].
Topics: Adult; Aged; Aged, 80 and over; Aminoglutethimide; Breast Neoplasms; Drug Resistance; Female; Humans | 1994 |
Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Axi | 1997 |
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Huma | 1992 |
Primary systemic therapy for operable breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Androstenedione; Antineoplastic Combined Chemotherapy Protocols; Aro | 1991 |
A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Doub | 1986 |
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer.
Topics: Aged; Aminoglutethimide; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Female; Hu | 1987 |
9 other studies available for aminoglutethimide and Lymph Node Metastasis
| Article | Year |
|---|---|
Prostate cancer metastasis to supraclavicular lymph node.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Prot | 2004 |
[Pharmacological suppression of the adrenal gland. Considerations on a clinical case].
Topics: Adenocarcinoma, Mucinous; Adrenocortical Hyperfunction; Adult; Aminoglutethimide; Antineoplastic Age | 1982 |
[The adjuvant hormonal therapy of breast cancer].
Topics: Aminoglutethimide; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Diethy | 1995 |
Aminoglutethimide (AG) and hydrocortisone (HC) in bone metastases: a retrospective study.
Topics: Adult; Aged; Aminoglutethimide; Bone Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; | 1993 |
Treatment of an adrenal cortical carcinoma with a combination of o,p'-DDD and aminoglutethimide.
Topics: 11-Hydroxycorticosteroids; Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenalectomy; Adult; | 1975 |
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.
Topics: Adult; Aged; Aminoglutethimide; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Follow- | 1992 |
pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response.
Topics: Aminoglutethimide; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immuno | 1991 |
[Endocrine therapy of breast cancer].
Topics: Aminoglutethimide; Antibodies, Monoclonal; Breast Neoplasms; Combined Modality Therapy; Female; Horm | 1987 |
[Which hormone therapy should be used in advanced breast carcinoma in males?].
Topics: Adenocarcinoma; Aged; Aminoglutethimide; Axilla; Breast Neoplasms; Dexamethasone; Drug Evaluation; H | 1988 |